摘要
目的促进吲哚布芬在住院患者中的合理应用。方法回顾性分析医院2019年1月至12月使用吲哚布芬的335例住院患者的病历,并对吲哚布芬适应证、用法用量、联合用药等的合理性,以及引发出血事件的原因进行分析。结果吲哚布芬主要用于预防心脑血管、血液透析的栓塞事件。患者平均年龄(63.40±17.33)岁;男212例(63.28%),女123例(36.72%);用药剂量为100~400 mg/d291例(86.87%)。引发出血事件48例(14.33%);联合使用其他抗栓药物219例(65.37%),其中联合使用活血化瘀中成药物106例(31.64%)。结论该院吲哚布芬使用存在适应证不合理、剂量不准确、联合用药不规范等问题,需进一步加强管理。
Objective To promote the rational application of indobufen in inpatients.Methods The medical records of 335inpatients using indobufen in the hospital from January to December 2019 were collected and retrospectively analyzed.The rationality of indications,usage,dosage,combination of drugs of indobufen and the causes of bleeding events were analyzed.Results Indobufen was mainly used to prevent embolism events in cardiac and cerebral vessels,hemodialysis.The average age of the patients was(63.40±17.33)years old,and there were 212 males(63.28%)and 123 females(36.72%).A total of291 cases(86.87%)used indobufen with the dosage of 100-400 mg/d,48 cases(14.33%)had bleeding events,and 219 cases(65.37%)used indobufen and other antithrombotic drugs,of whom 106 cases(31.64%)used indobufen and Chinese patent drugs for promoting blood circulation and removing blood stasis.Conclusion The use of indobufen in this hospital has problems such as unreasonable indications,inaccurate dosage and nonstandard combination of drugs,which need to be further strengthened.
作者
粟林
赖翔宇
李拓颖
敬怀志
SU Lin;LAI Xiangyu;LI Tuoying;JING Huaizhi(Chongqing University Cancer Hospital,Chongqing,China 400030;Mianyang Hospital Affiliated to School of Medicine,University of Electronic Science and Technology of China·Mianyang Central Hospital,Mianyang,Sichuan,China 621000)
出处
《中国药业》
CAS
2022年第19期111-114,共4页
China Pharmaceuticals
基金
重庆市科卫联合医学科研项目[2021MSXM171]
四川省医学(青年创新)科研课题[Q19006]。
